Protocol Ledger

NCT04191499 · Phase II/III · ACTIVE NOT RECRUITING

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced o

Interventional Phase II/III clinical trial protocol NCT04191499 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-29 Enrollment: 325 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04191499
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)325 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04191499
Protocol FieldVerified Registry Value
NCT IdentifierNCT04191499
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment325 participants (ACTUAL)
Registered Start Date2020-01-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI